Showing 181 - 200 results of 17,434 for search '(( 50 ((((n decrease) OR (a decrease))) OR (mean decrease)) ) OR ( 100 nm decrease ))', query time: 0.48s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187
  8. 188

    mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

    Published 2019
    “…(<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
  9. 189
  10. 190
  11. 191

    m 6A RNA Methylation Decreases Atherosclerotic Vulnerable Plaque Through Inducing T Cells by Chunmei Qi (739294)

    Published 2023
    “…<div><p>ABSTRACT Introduction: Knockdown of fat mass and obesity-associated gene (FTO) can induce N6-methyladenosine (m 6A) ribonucleic acid (RNA) methylation. …”
  12. 192
  13. 193
  14. 194

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  15. 195

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  16. 196
  17. 197
  18. 198
  19. 199
  20. 200